Discovery and bioassay of disubstituted β-elemene-NO donor conjugates:synergistic enhancement in the treatment of leukemia

作     者：ZHU Junlong JIANG Xiaoying LUO Xinyu GAO Yuan ZHAO Rui LI Junjie CAI Hong DANG Xiawen YE Xiangyang BAI Renren XIE Tian ZHU Junlong;JIANG Xiaoying;LUO Xinyu;GAO Yuan;ZHAO Rui;LI Junjie;CAI Hong;DANG Xiawen;YE Xiangyang;BAI Renren;XIE Tian

作者机构：School of PharmacyHangzhou Normal UniversityHangzhou 311121China Key Laboratory of Elemene Class Anti-cancer Chinese MedicinesEngineering Laboratory of Development and Application of Traditional Chinese MedicinesCollaborative Innovation Center of Traditional Chinese Medicines of Zhejiang ProvinceHangzhou Normal UniversityHangzhou 311121China 

出 版 物：《Chinese Journal of Natural Medicines》 (中国天然药物（英文版）)

年 卷 期：2023年第21卷第12期

页      面：916-926页

核心收录：

学科分类：1008[医学-中药学(可授医学、理学学位)] 1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 1002[医学-临床医学] 100602[医学-中西医结合临床] 10[医学] 

基　　金：This project was supported by the Natural Science Foundation of Zhejiang province(No.LY20H300004) the National Natural Science Foundation of China(Nos.82073686,81730108,and 81973635) Scientific Research Foundation for Scholars of HZNU(Nos.2021QDL026 and 2019QDL003) the Ministry of Science and Technology of China(High-end foreign experts program,Nos.G20200217005 and G2021017004) 

主　　题：Antitumor activity Chronic myeloid leukemia β-elemene Nitric oxide donor Structural modification 

摘      要：Natural products are essential sources of antitumor *** such molecule,β-elemene,is a potent antitumor compound extracted from Curcuma *** the present investigation,a series of novel 13,14-disubstituted nitric oxide(NO)-donorβelemene derivatives were designed,withβ-elemene as the foundational compound,and subsequently synthesized to evaluate their therapeutic potential against ***,the derivative labeled as compound 13d demonstrated a potent anti-proliferative activity against the K562 cell line,with a high NO *** vivo studies indicated that compound 13d could effectively inhibit tumor growth,exhibiting no discernible toxic ***,a significant tumor growth inhibition rate of 62.9%was observed in the K562 xenograft tumor mouse *** accumulated data propound the potential therapeutic application of compound 13d in the management of leukemia.